A new method to deliver cancer treatment directly to the bladder
An urinary drug disposing approach for treatment of bladder Cancer
['FUNDING_R01'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-10887643
This study is testing a new way to deliver bladder cancer treatment through an IV, which could make it easier for patients and help prevent the cancer from coming back.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10887643 on ClinicalTrials.gov |
What this research studies
This research focuses on improving bladder cancer treatment by developing a new drug delivery method that addresses the limitations of current therapies. Most bladder cancer patients are treated with intravesical immunotherapy or chemotherapy, which can be invasive and often ineffective for tumors in the upper urinary tract. The study proposes using a bio-inert peptide that can be administered intravenously, allowing for better distribution of the treatment throughout the urinary system. This approach aims to enhance patient compliance and reduce recurrence rates of bladder cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-muscle invasive bladder cancer who are seeking alternative treatment options.
Not a fit: Patients with muscle invasive bladder cancer who are eligible for radical cystectomy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective bladder cancer treatments and improved survival rates for patients.
How similar studies have performed: While this approach is innovative, similar research has shown promise in improving drug delivery methods for other types of cancers.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LAW, BENEDICT SHEK HANG — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: LAW, BENEDICT SHEK HANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.